Drugs / PROSTVAC-V
PROSTVAC-V
also known as
PROSTVAC-V/TRICOM · Rilimogene Galvacirepvec · PROSTVAC V/F · Recombinant Vaccinia-PSA (L155)-TRICOM
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03532217 | Sep 2018 → Apr 2022 | metastatic prostate carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00113984 | Jun 2005 → Feb 2008 | prostate neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/22 trials · 1 met primary | ||||||
| Phase 1/2 | NCT02933255 | Apr 2017 → Jun 2023 | prostate cancer | National Cancer Institute (NCI) | Completed | Met primary |
| Phase 1/2 | NCT00060528 | May 2003 → Mar 2006 | prostate neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 211 trials · 3 missed | ||||||
| Phase 2 | NCT03315871 | Mar 2018 → Jun 2024 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02506114 | Oct 2016 → Apr 2020 | prostate neoplasm | Lawrence Fong | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02772562 | Jul 2016 → Apr 2024 | prostate cancer | Medical University of South Carolina | Terminated | No outcome recorded |
| Phase 2 | NCT02649855 | Jan 2016 → Jul 2022 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02649439 | Dec 2015 → Mar 2019 | prostate cancer | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT02326805 | Jun 2015 → Nov 2018 | prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02153918 | May 2014 → Jul 2017 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01875250 | Jul 2013 → Sep 2019 | prostate cancer | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT01145508 | Aug 2010 → Oct 2012 | hormone-resistant prostate carcinoma, prostate adenocarcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00450463 | Feb 2007 → Apr 2017 | prostate cancer | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT00108732 | Feb 2006 → Oct 2010 | grade III prostatic intraepithelial neoplasia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01322490 | Nov 2011 → Sep 2017 | metastatic prostate carcinoma | Bavarian Nordic | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PROSTVAC-V | “PROSTVAC-V (Vaccinia)/TRICOM” NCT00108732 ↗ |
| Known as | PROSTVAC V/F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02506114 ↗ |
| Known as | PROSTVAC-V/TRICOM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02153918 ↗ |
| Known as | Recombinant Vaccinia-PSA (L155)-TRICOM | “Drug: Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)” NCT00060528 ↗ |
| Known as | Rilimogene Galvacirepvec | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01145508 ↗ |
| Action | Deplete | “The immune stimulating vaccine will help white blood cells recognize and kill the cancer cells throughout the body.” NCT01875250 ↗ |
| Modality | Vaccine | “a vaccine using recombinant vaccinia virus (prime) and recombinant fowlpox virus (boost)” PMID 17707059 ↗ Aug 2007 |
| Route | Subcutaneous | “Given SC” NCT00108732 ↗ |